Ms. Snowden founded NCGS in 1984 and brings over 30 years of diversified medical and business experience to the helm. Previous to the inception of NCGS, Ms. Snowden served in critical roles as a Senior Research Coordinator, Oncology Clinical Research Coordinator and as a MICU Charge Nurse. Her clinical trial experience includes oncology, HIV / AIDS, AIDS related disorders, transplant medicine, infectious disease, women’s health, wound healing and novel diagnostic products. Ms. Snowden is a recognized advisor and industry speaker regarding clinical research and trial management, performance metrics, data analytics/risk mitigation, quality models, trial rescues, HIV treatment, Infectious Disease treatment, Sepsis treatment, cancer therapies, oncology patient care, and cancer nutrition. Ms. Snowden has a Registered Nursing Degree and continues to expand her knowledge base by attending educational seminars in research methodologies, business management, data management, and statistical analysis.
JANICE E. DURDENPARTNER & SVP OF CLINICAL OPERATIONS
Ms. Durden holds a Bachelor of Science Degree in Microbiology from Clemson University and a Masters in Business from the Citadel. Ms. Durden has experience in both clinical and diagnostic trials beginning her career in 1996 at Organon Teknika and joining NCGS initially in 1997 focusing on infectious disease and critical care trials. She returned to NCGS in 2003 as Director of Clinical Operations and Implementation and rose to the position of Vice President and Partner. Clinical focuses include: trial rescue, oncology, infectious disease, neuro-pysch, women’s health and QT prolongation trials. Currently, Ms. Durden is the VP of Clinical Operations and heads a pivotal rapid deployment team that plays a role in launching key studies or takeover of ongoing trials that require additional staffing for timely completion.
DOUG SNOWDENPARTNER & TECHNOLOGY INNOVATION LEAD
ALICE BARUCH, MD, PHDGLOBAL MEDICAL DIRECTOR
Dr. Baruch has over 20 years of experience in every phase of clinical drug development across multiple therapeutic areas, with 11 NDA/sNDA submissions. She has complex international study and team management experience; implementing strategies to complete studies early with multimillion dollar savings. Prior to joining NCGS, Dr. Baruch held positions at several large pharmaceutical companies including Pfizer, Janssen, and Hoffmann-La Roche. Dr. Baruch’s clinical proficiency and professionalism, combined with broad industry experience, provides unique vision and skill to meld depth of technical study know-how with medical insight and knowledge. Her passionate commitment to excellence in leveraging expert synthesis of clinical and safety data, in conjunction with skilled writing, has resulted in multiple successful drug approvals and international regulatory submissions, as well as major NGO grants. Dr. Baruch received her medical degree from Columbia University, New York Hospital and Columbia- Presbyterian Medical Center. Her research focus includes Infectious Disease and more recently Oncology.
KATHLEEN EDWARDS, CPAVP, FINANCE
THOMAS HARTVP, IMPLEMENTATION
JOHN WALLGENERAL COUNSEL
DAVID MCCRARY, MBADIRECTOR, BUSINESS DEVELOPMENT
JENNIFER ZIMMERMAN, RN, BSNDIRECTOR, QUALITY ASSURANCE